Factors associated with outcome in a national cohort of rhinovirus hospitalized patients in Brazil in 2022.

The common cold is the primary cause of illness in the community, with over 200 viral strains identified, and rhinovirus infections being the most prevalent. Coronavirus Disease 19 (COVID-19) is also a significant cause of severe illness. The burden of acute respiratory infections has a significant impact on the economy, resulting in absenteeism from work and school. Rhinovirus infections can exacerbate asthma and other chronic diseases, leading to hospitalization. The objective of this study is to investigate the factors associated with death and survival in patients hospitalized for rhinovirus in Brazil in 2022. This is a retrospective cohort study using data from the national surveillance of Severe Acute Respiratory Syndrome (SARS) in 2022 in Brazil, with all the norrifications. We analysed and compared clinical and epidemiological factors and outcomes between survivors and deaths in patients hospitalised for rhinovirus. The absolute and relative frequencies were calculated according to the states. Bivariate analysis was performed using chi-squared test and Fisher's exact test, while multivariate analysis was performed using COX regression. Out of 8,130 cases of SARS caused by rhinovirus, 291 (3.58%) resulted in death while 7839 (96.47%) patients survived. The factors associated with death were invasive ventilation (p- < 0.001 HR 4.888 CI 95% 3.816-6.262), bocavirus (p- < 0.001 HR 4.204 CI 95% 2.595-6.812), immunodepression/Immunosuppression (p- < 0.001 HR 2.417 CI 95% 1. 544-3, 786), COVID-19 (p- < 0.001 HR 2.167 CI 95% 1.495-3.142), chronic neurological diseases (p-0.007 HR 1.610 CI 95% 1.137-2.280), abdominal pain (p-0.005 HR 1.734 CI 95% 1.186-2.537), age (p- < 0.001 HR 1.038 CI 95% 1.034-1.042). The survival factors identified in this study were dyspnea (p = 0.005; HR 0.683; CI 95% 0.524-0.889), cough (p < 0.001; HR 0.603; CI 95% 0.472-0.769), and asthma (p = 0.052; HR 0.583; CI 95% 0.339-1.004). Additionally, the study found that receiving a COVID-19 booster dose was also a significant survival factor (p = 0.001; HR 0.570; CI 95% 0.415-0.784). The factors associated with death were similar to those in the literature, and the factors associated with survival were also similar, except for the booster dose of the COVID-19 vaccine, which we didn't find in any studies. Our study is the first to associate the full course of the COVID-19 vaccine with survival in those hospitalized for rhinovirus, regardless of COVID-19 and rhinovirus co-detection.